Get full text access Log in, subscribe or purchase for full access. References 1. Ben-David, R. ∙ Eraky, A. ∙ Hug, B. ... Clinical utility of tumour-informed circulating tumour DNA in patients with testicular cancer BJU Int. 2025; 136:1098-1106 2. Hassoun, R. ∙ Ben-David, R. ∙ Sfakianos, J.P. ... Longitudinal evaluation of circulating tumor DNA as a prognostic biomarker to detect molecular residual disease in germ cell tumors JCO Precis Oncol. 2025; 9, e2500176 Erratum. In: JCO Precis Oncol 2026;10:e2600181
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Scott Eggener
Prostate Cancer Mortality After Relabeling Low-Grade Prostate Cancer as Precancerous
Key Points Question What are the effects of relabeling low-grade prostate cancer as a precancerous condition on prostate cancer mortality? Findings In this decision analytical model study, the number of prostate cancer deaths in the US avoided by relabeling compared with increased mortality was modeled. In the base case, relabeling would lead to 6-fold more annual prostate deaths avoided than caused (2835 vs 452), and relabeling reduced deaths in all reasonable modeling scenarios.
Stockholm3 Versus Prostate-specific Antigen in Prostate Cancer Screening: 9-year Outcomes Demonstrating Improved Detection of Aggressive Cancers and Reduced Overdiagnosis from the STHLM3 Trial
Keywords Prostate cancer Biochemical recurrence Prostate-specific antigen threshold Stockholm3 Prostate cancer screening Risk stratification Population-based trial Prostate-specific antigen Multimodal biomarker testing Prostate cancer mortality What does this study add?
MXene and prostate cancer: is there promising news?
Potential for improved prostate cancer diagnostics: MXenes offer significant advantages for prostate cancer diagnostics, including higher sensitivity and specificity for the detection of biomarkers such as PSA. Their unique structure and conductivity have enabled the development of highly sensitive biosensors that can improve early detection and monitoring.
Primary retroperitoneal lymph node dissection in clinical stage 2a/b non‐seminomatous germ cell tumour
Supporting Information Filename Description bju16618-sup-0001-Supplementaryfile1.docxWord 2007 document , 1 MB File S1. Data analysis excluding the main contributing centre. bju16618-sup-0002-Supplementaryfigure1.docxWord 2007 document , 438 KB Figure S1. Kaplan–Meier estimates of disease-free survival (DFS), stratified by number of cycles of adjuvant chemotherapy. bju16618-sup-0003-Supplementarytable1.docxWord 2007 document , 27.4 KB Table S1.
Leveraging Cutting-Edge Technologies to Enhance Prostate Cancer Treatments "Presentation" - Scott Eggener
Read the Full Video Transcript Gordon: I have the distinct pleasure of inviting Dr. Eggener to the podium to give us a discussion around leveraging cutting-edge technologies in the management of prostate cancer patient treatment options. He's the professor of urology at the University of Chicago School of Medicine, the vice chair, Section of Urology, and he currently is the director of High Risk and Advanced Prostate Cancer, a prolific academic surgeon, and an all-around great human being.
Welcome and Background Cancer or Not Cancer "Presentation" - Scott Eggener
Read the Full Video Transcript Scott Eggener: The public health would be improved if Grade Group 1 was no longer called cancer. And we've tacitly been moving in that direction. There's a whole bunch of biomarkers that look not to diagnose Grade Group 1; that's the main attraction, it's one of the main attractions of MRI.
Welcome and Background for This Meeting "Presentation" - Scott Eggener
Read the Full Video Transcript Scott Eggener: The public health would be improved if Grade Group 1 was no longer called cancer. And we've tacitly been moving in that direction. There's a whole bunch of biomarkers that look not to diagnose Grade Group 1; that's the main attraction, it's one of the main attractions of MRI.
No todo lo que denominamos cáncer debe ser llamado así
“Tienes cáncer”. Puedes preguntárselo a cualquiera que le hayan dicho eso: es aterrador. Esa es una de las razones por las que debemos replantearnos lo que llamamos cáncer.
Not everything we call cancer should be called cancer
Not everything we call cancer should be called cancer Calling something cancer can lead to aggressive treatment even if the cancer in question is unlikely to cause problems. Carolina Moscoso for The New York Times By Laura Esserman and Scott Eggener Published: Tue 5 Sep 2023, 10:14 PM “You have cancer.” Ask anyone who has been told this: It’s terrifying. That’s one reason we need to rethink what we call cancer.
Pre-Cancer- OverDiagnoses, OverTreatment?
Dr. Esserman is a surgeon and breast cancer oncologist at the University of California, San Francisco. Dr. Eggener is a surgeon and urologic oncologist at the University of Chicago. “You Have Cancer.” Ask anyone who has been told this: It’s terrifying. That’s one reason we need to rethink what we call cancer. Despite amazing advances in our understanding of the disease, we have neglected to update how we define what has been called the emperor of all maladies.
Not Everything We Call Cancer Should Be Called Cancer
“You have cancer.” Ask anyone who has been told this: It’s terrifying. That’s one reason we need to rethink what we call cancer. Despite amazing advances in our understanding of the disease, we have neglected to update how we define what has been called “the emperor of all maladies.” Some cancers have extraordinarily low risks of altering the quality or length of life but get lumped in with those that do.
Not Everything We Call Cancer Should Be Called Cancer
Laura Esserman and "You have cancer." Ask anyone who has been told this: It's terrifying. That's one reason we need to rethink what we call cancer. Despite amazing advances in our understanding of the disease, we have neglected to update how we define what has been called the emperor of all maladies. Some cancers have extraordinarily low risks of altering the quality or length of life but get lumped in with those that do.
The Emotional Toll of Surgical Complications - Scott Eggener
Read the Full Video Transcript Zach Klaassen: Hi, my name is Dr. Zach Klaassen. I'm a urologic oncologist at the Georgia Cancer Center in Augusta, Georgia. Thank you for joining us for this UroToday discussion with Dr. Scott Eggener who is a Professor of Urology at the University of Chicago. Dr. Eggener, thanks so much for joining us today. Scott Eggener: Yeah, thanks for having me, Dr. Klaassen. Zach Klaassen: Awesome.
Removing the Designation of Cancer from Grade Group 1 Disease Will Do More Good than Harm
Netto et al [] argue against recent proposals to avoid the term “cancer” when only grade group 1 (GG1) disease is found on prostate biopsy. One “strong rationale” is that “pattern 3 cancer shares many morphologic and canonical molecular alterations associated with higher-grade prostate adenocarcinoma” []. This provides a clear contrast to the views of advocates for redesignating pattern 3 as noncancer.
Low-Grade Prostate Cancer: Time to Stop Calling It Cancer
Introduction Prostate-specific antigen (PSA) screening for prostate cancer (PCa) remains highly controversial, largely because it is unclear whether the primary benefits of reducing rates of metastases and cancer mortality are worth the risks of overdiagnosis, overtreatment, and potential treatment-related morbidity.
Low-Grade Prostate Cancer: Time to Stop Calling It Cancer
Scott E. Eggener , MD1; Alejandro Berlin , MD2; Andrew J. Vickers , PhD3; Gladell P. Paner, MD4; Howard Wolinsky 5; and Matthew R.
Deconstructing, Addressing, and Eliminating Racial and Ethnic Inequities in Prostate Cancer Care
Abstract Men of African ancestry have demonstrated markedly higher rates of prostate cancer mortality than men of other races and ethnicities around the world. In fact, the highest rates of prostate cancer mortality worldwide are found in the Caribbean and Sub-Saharan West Africa, and among men of African descent in the USA.
Radical Prostatectomy Without Biopsy: Audacious, Imprudent, or Innovative?
In this issue of European Urology, Meissner and colleagues [] present data for a series of 25 men who underwent radical prostatectomy without preoperative histologic confirmation of prostate cancer, instead relying on highly suspicious results from multiparametric magnetic resonance imaging (MRI; Prostate Imaging-Reporting and Data System score ≥4) and a prostate-specific membrane antigen (PSMA) positron emission tomography (PET) scan (≥4 on a 5-point Likert scale and maximum standardized...
Re: NCCN Prostate Cancer Guidelines Version 1.2022 - September 10, 2021
Jeremy Grummet Jeremy Grummet Correspondence Corresponding author at: Section of Urology, Department of Surgery, Alfred Health Central Clinical School, Monash University, Melbourne, Australia. Affiliations Section of Urology, Department of Surgery, Alfred Health Central Clinical School, Monash University, Melbourne, Australia Search for articles by this author Scott Eggener
An Unusual Case of Resistant Hypertension Secondary to Fibromuscular Dysplasia:
Abstract A 28-year-old woman with resistant hypertension was given a diagnosis of fibromuscular dysplasia with 100% occlusion of a right renal artery branch supplying an atrophied lower pole, collateralized by the right adrenal artery. Successful adrenal collateral coil embolization restored normotension, but hypertension recurred, necessitating right partial heminephrectomy with blood pressure normalization off medications.
Re: Pretransplant Solid Organ Malignancy and Organ Transplant Candidacy: A Consensus Expert Opinion Statement
Scott E. Eggener Scott E. Eggener Correspondence Corresponding author. Department of Surgery, University of Chicago, 5841 South Maryland Avenue, Chicago, IL 60637, USA. Affiliations University of Chicago Medicine, Chicago, IL, USA Search for articles by this author Piyush K. Agarwal To read this article in full you will need to make a payment Subscribe to European Urology References Liauw S.L. Ham S.A. Das L.C. et al.
An Expert Discussion on Gleason 6 (Grade Group 1) Prostate Cancer - Scott Eggener
Read the Full Video Transcript Matt Cooperberg: Good morning, good afternoon, depending on where you are. Welcome to a Zoom edition of the Uro Today Localized Prostate Cancer Center of Excellence. It's a pleasure to be joined today by Dr. Scott Eggener. Dr. Eggener is the Bruce and Beth White Family Professor of Surgery and Radiology at the University of Chicago, where he is Vice-Chair of the department and also directs the High Risk and Advanced Prostate Cancer Clinic.
Increasing incidence of testicular cancer in the United States and Europe between 1992 and 2009
Abstract Purpose Increasing in incidence, testicular cancer is the most commonly diagnosed cancer in young men in the USA and in Europe. We sought to determine contemporary trends in testicular cancer incidence in the USA and Europe. Methods Testicular cancer incidence data covering the USA and Europe were extracted from the SEER-13 (SEER*Stat 8.0.1) and the EUREG databases, respectively.
Prostate-specific Antigen to Predict Early Success of Focal Therapy: Focusing on Appropriate Endpoints
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Although there is a wide spectrum of prostate cancer characteristics and risk, management strategies for localized disease typically consist of a binary option: whole-gland therapy or observation. Focal therapy (partial gland ablation) offers the enticing possibility of an intermediate option that meets a patient’s oncologic and safety goals.
Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline
With panel representation from the American Urological Association (AUA), the College of American Pathologists (CAP), and European Association of Urology (EAU). At the time of publication, this ASCO Guideline has been endorsed by the EAU.
Best Practice Statement | Journal of Urology
Purpose: We update the prior AUA SOP for MRI of the prostate and summarize the available data about the technique and clinical use of MRI in the diagnosis and management of prostate cancer. This updated SOP provides practical recommendations for MRI use in the screening, diagnosis, staging, treatment, and surveillance of prostate cancer.
Recurrence After Robotic Retroperitoneal Lymph Node Dissection Raises More Questions than Answers
Adverse Surgical Outcomes Associated with Robotic Retroperitoneal Lymph Node Dissection Among Patients with Testicular Cancer
Patient-reported Outcomes and Late Toxicity After Postprostatectomy Intensity-modulated Radiation Therapy
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Fig. 1 Patient-reported quality of life over time for major quality-of-life domains. Fig. 2 Changes in erectile function over time stratified by those with baseline function versus no baseline function. Fig. 3 Urinary quality of life (normalized to 0–100, with 100 being the best health) comparing pad usage at baseline prior to postoperative radiation therapy.
Lymph node count impacts survival following post‐chemotherapy retroperitoneal lymphadenectomy for non‐seminomatous testicular cancer: a population‐based analysis - Bhanvadia - - BJU International - Wiley Online Library
The full text of this article hosted at iucr.org is unavailable due to technical difficulties. Original Article Lymph node count impacts survival following post‐chemotherapy retroperitoneal lymphadenectomy for non‐seminomatous testicular cancer: a population‐based analysis Raj R. Bhanvadia Corresponding Author E-mail address: raj.bhanvadia@phhs.org https://orcid.org/0000-0003-3462-376X Section of Urology, Department of Surgery, University of Chicago, Chicago, IL, USA Correspondence: Raj R.
Re: Use of Active Surveillance or Watchful Waiting for Low-risk Prostate Cancer and Management Trends Across Risk Groups in the United States 2010-2015 - European Urology
If you are a current subscriber with Society Membership or an Account Number, claim your access now. Purchase a subscription to gain access to this and all other articles in this journal. Visit ScienceDirect to see if you have access via your institution.
Obscenity, Michael Jordan, and Measuring Outcomes: Explaining and Improving the Quality of Kidney Cancer Care
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Every urology trainee quickly recognizes variability regarding surgical indications, technical skill, efficiency, and postoperative management, particularly for complex surgeries such as partial nephrectomy.
“Real-world” Practice Makes Perfect: Ensuring the Active Component of Active Surveillance for Prostate Cancer
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Active surveillance for low-risk prostate cancer has dramatically risen in popularity as a means of minimizing unnecessary treatment without compromising long-term cancer-related outcomes. In a recent population-based study from Sweden, active surveillance was the initial management for 74% of men with low-risk disease and 91% of men with very low risk [1].
Nodal Metastases at Radical Prostatectomy: More Aggressive Disease Warrants Consideration of Multimodal Treatment
Overall, there is sparse high-level data to guide the management of occult cancer identified within the pelvic lymph nodes following prostatectomy (cN0pN1). Nearly every urologist is familiar with the (Eastern Cooperative Oncology Group 3886) favoring immediate castration over delayed castration at metastasis [1][1].
Contents - European Urology
EAU–ESTRO–SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent By: Nicolas Mottet, ... , Philip Cornford Nicolas Mottet, Joaquim Bellmunt, Michel Bolla, Erik Briers, Marcus G. Cumberbatch, Maria De Santis, Nicola Fossati, Tobias Gross, Ann M. Henry, Steven Joniau, Thomas B. Lam, Malcolm D. Mason, Vsevolod B. Matveev, Paul C. Moldovan, Roderick C.N. van den Bergh, Thomas Van den Broeck, Henk G. van der Poel, Theo H.
Generalizability of Clinical Trials: Why It Matters for Patients and Public Policy
Refers to article: Generalizability of the Prostate Cancer Intervention Versus Observation Trial (PIVOT) Results to Contemporary North American Men with Prostate Cancer Deepansh Dalela, Patrick Karabon, Jesse Sammon, Akshay Sood, Björn Löppenberg, Quoc-Dien Trinh, Mani Menon and Firas Abdollah Accepted 22 August 2016 Abstract Full Text Full-Text PDF (644 KB) Department of Surgery, University of Chicago, Chicago, IL, USA ?
New and Established Technology in Focal Ablation of the Prostate: A Systematic Review
Focal therapy of prostate cancer has been proposed as an alternative to whole-gland treatments. To summarize the evidence regarding sources of energy employed in focal therapy. Embase and Medline (PubMed) were searched from 1996 to October 31, 2015 following the Preferred Reporting Items for Systematic Reviews and Meta-analyses statement. Ongoing trials were selected from electronic registries.
Prostate Cancer Screening Biomarkers: An Emerging Embarrassment of ‘Riches’?
Refers to article: Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment Scott A. Tomlins, John R. Day, Robert J. Lonigro, Daniel H. Hovelson, Javed Siddiqui, L. Priya Kunju, Rodney L. Dunn, Sarah Meyer, Petrea Hodge, Jack Groskopf, John T. Wei and Arul M. Chinnaiyan Accepted 29 April 2015 July 2016 (Vol.
Patient-Initiated Prostate Cancer Screening Among Older U.S. Men
The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities.
Murderer in the Mirror
The End is a series about end-of-life issues. “What happened? Is he all right?” Telling the family is devastating. It only gets worse. He trusted me with his life. He bled to death before my eyes. Belly open, my hands inside him. This is the toughest encounter I’ve ever experienced, an emotional tsunami I was not prepared to handle. He will not say goodbye to his kids, experience the joy of his soon-to-be-born grandchild sitting on his lap, see another sunset, hold his wife’s hand ever again.
Murderer in the Mirror
“What happened? Is he all right?” Telling the family is devastating. It only gets worse. He trusted me with his life. He bled to death before my eyes. Belly open, my hands inside him. This is the toughest encounter I’ve ever experienced, an emotional tsunami I was not prepared to handle. He will not say goodbye to his kids, experience the joy of his soon-to-be-born grandchild sitting on his lap, see another sunset, hold his wife’s hand ever again. His wife and son’s tears emerge and become my focus.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Scott
Contact Scott, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack